Inhibrx Biosciences, Inc.

Healthcare

NASDAQ:INBX · NASDAQ Global Market

Market Cap $1.37B Beta 3.32 P/E (TTM) -11.0

$93.05 -2.74%

-$2.58 today

52W Low $13.97High $155.29

Vol 0.42M · Avg 0.43M

EPS (TTM) -$8.35Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+539.08%

Period High

$141.84

Period Low

$14.27

Latest

$93.05

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Relay Therapeutics, Inc.

NASDAQ:RLAY

$2.78B

Enliven Therapeutics, Inc.

NASDAQ:ELVN

$2.73B

Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

$1.68B

Atai Beckley Inc.

NASDAQ:ATAI

$1.47B

Immatics N.V.

NASDAQ:IMTX

$1.30B

Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

$1.28B

Nektar Therapeutics

NASDAQ:NKTR

$1.16B

CureVac N.V.

CVAC

$1.05B

ORIC Pharmaceuticals, Inc.

NASDAQ:ORIC

$880.93M

Sana Biotechnology, Inc.

NASDAQ:SANA

$843.22M

What is the latest INBX filing?

The latest filing shown is 8-K dated Jun 15, 2026.

How many recent filings does INBX have?

Intrinsic Alpha currently shows 20 recent filings for INBX.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.